The legal fight for control of CytoDyn Inc. spread to a second forum, when investors backing a dissident slate of board nominees—whom the drugmaker sued three weeks ago in federal court in Delaware—filed suit in state court against the company and its current directors.
The lawsuit was filed Wednesday in Delaware Chancery Court by Paul A. Rosenbaum, Jeffrey P. Beaty, and Arthur L. Wilmes, who are leading a proxy battle aimed at taking over the board at the company’s annual meeting in October. It targets CytoDyn, CEO Nader Z. Pourhassan, and five other directors.
The lawsuit, which refers to the ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.